This article came out June 22nd 2018. I remember posting it when it came out, but here it is again.
https://www.fool.ca/2018/06/22/young-investors-3-biotech-stocks-that-can-electrify-your-tfsa/
Resverlogix is the last of the three companies mentioned, the other two being Zymeworks fist (ZYME) and Aptose second (APS). If someone bought all three they're likely wishing they'd skipped the first two mentioned. Over the last 6 months ZYME is down almost 30% and APS is down over 50%.
Here's the comparison chart for the 6 months since the article came out..
